COCP - Cocrystal Pharma extends drug discovery collaboration with Hitgen and Interx

Cocrystal Pharma (COCP) announces an extension of its drug discovery collaboration with HitGen and computer software company InterX with the agreement now continuing through August 2023.Through the collaboration, Cocrystal, HitGen and InterX scientists are applying HitGen’s DNA-encoded library ((DEL)) technology platform, Cocrystal’s structure-based drug discovery platform technology, and InterX’s computational science to develop novel antiviral lead candidates.A Joint Steering Committee comprised of representatives from all three companies is overseeing the collaboration."We view this collaboration as a long-term relationship with the potential to build Cocrystal’s platform and expand our pipeline with high-value compounds for future development," Cocrystal CEO Gary Wilcox said.Cocrystal shares up nearly 3% premarket.

For further details see:

Cocrystal Pharma extends drug discovery collaboration with Hitgen and Interx